{"nctId":"NCT05498467","briefTitle":"The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis","startDateStruct":{"date":"2022-10-11","type":"ACTUAL"},"conditions":["Allergic Contact Dermatitis"],"count":20,"armGroups":[{"label":"Anakinra","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Anakinra"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Sodium Chloride 9mg/ml Injection"]}],"interventions":[{"name":"Anakinra","otherNames":[]},{"name":"Sodium Chloride 9mg/ml Injection","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged at least eighteen years old.\n* Able to provide written informed consent.\n* Have a medical diagnosis of nickel allergy with at least a +2 reaction on the\n* ICDRG scoring system when challenged with nickel.\n* Fitzpatrick skin type 1-4.\n* Able to speak and understand Danish.\n\nExclusion Criteria:\n\n* Received any topical immunomodulating or immunosuppresive treatment on the lower back two weeks prior, or applied cr√®me/lotion on the lower back 24 hours prior to day 0.\n* Received systemic immunomodulating or immunosuppressive treatment four weeks prior to day 0.\n* Any skin lesions at the area of interest such as nevi, scar tissue or pigment changes.\n* Dermatitis and/or infection.\n* Recent (3 months or less) administration of a live virus vaccine.\n* Women of childbearing potential who are not taking adequate contraception or who are pregnant, plan to become pregnant during the study duration or lactating.\n* Taking part in any other intervention study.\n* Has any other condition which would, in the Investigator's opinion, deem the patient unsuitable for participation in the study (e.g. condition requiring long term or frequent oral steroid use).\n* Presence of any condition or use of any medication which precludes the use of the study drug.\n* Allergy to any of the ingredients in the drug.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Reaction","description":"Number of participants with a lower clinical ICDRGscoring in the active treatment group compared to placebo","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":[]}}}